MergerJun 10, 2026, 08:02 AM
Aptorum Group Shareholders Approve DiamiR Biosciences Merger
AI Summary
Aptorum Group Ltd. announced that its shareholders, along with DiamiR Biosciences Corp.'s shareholders, approved the proposed all-stock merger transaction. This approval is a significant step towards DiamiR becoming a wholly-owned subsidiary of Aptorum Group. At the Extraordinary General Meeting, Aptorum shareholders also approved a share consolidation, domestication to Delaware, issuance of new stock for the merger, a new stock incentive plan, and the appointment of five directors for the post-merger company. The merger is expected to close before fiscal 2027, subject to remaining closing conditions.
Key Highlights
- Aptorum Group shareholders approved the all-stock merger with DiamiR Biosciences Corp.
- DiamiR Biosciences shareholders also approved the merger transaction on June 9, 2026.
- Shareholders approved a share consolidation at a ratio of 2-1 to 10-1.
- Approved domestication from the Cayman Islands to the State of Delaware.
- Approved issuance of over 20% of Aptorum Delaware common stock to DiamiR stockholders.
- Approved a new stock incentive plan with 4,500,000 shares of Common Stock.
- Approved appointment of five directors to the post-merger Board of Directors.
- Merger completion is subject to remaining closing conditions, expected before fiscal 2027.
Price Impact